November 7, 2015
Galeterone Shows Anti-Tumor Activity in Multiple Pre-Clinical Models that Express Androgen Receptor Splice Variants, Supporting Correlative Patient Data Seen in ARMOR2. Jacoby, D., et al. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015.
October 8, 2015
Implementing a CTC-Based Clinical Trial Assay for Selecting AR-V7 + Patients for Enrollment in a Pivotal Phase 3 Study (ARMOR-SV). Dransfield, D., et al. Prostate Cancer Foundation Annual Scientific Retreat 2015.
May 30, 2015
Androgen Receptor Modulation Optimized for Response: Splice Variant (ARMOR3-SV) — Randomized, Open-label, Multicenter, Controlled Study of Galeterone vs Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Expressing AR-V7 Splice Variant. Taplin, M-E., et al. American Society of Clinical Oncology Annual Meeting 2015. Abstract Number TPS5069.
April 20, 2015
Galeterone and Its Novel Analogs Induce Profound Anti-Cancer Activities in Human Pancreatic Cancer Cell Lines. Kwegyir-Afful, A.K., et al. 2015 American Association for Cancer Research (AACR) Annual Meeting. Abstract Number 1764.
September 29, 2014
Galeterone in Four Castrate Resistant Prostate Cancer (CRPC) Populations: Results from ARMOR2. Taplin, M-E., et al. European Society for Medical Oncology (ESMO) 2014 Congress.
May 31, 2014
Galeterone in men with CRPC: Results in Four Distinct Patient Populations from the ARMOR2 Study. Montgomery, R., et al. 2014 American Society of Clinical Oncology (ASCO), Abstract #5029.
January 30, 2014
ARMOR2: Galeterone in Progressive CRPC Patients Who Have Failed Primary Therapy. Taplin, M, et al. 2014 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Abstract #71.
October 22, 2013
Galeterone Suppresses Castration-Resistant and Enzalutamide-Resistant Prostate Cancer Growth in Vitro. Al Nakouzi, N, et al. AACR-NCI-EORTC 2013 International Conference on Molecular Targets and Cancer Therapeutics, Abstract #C89.
May 15, 2013
Comparison of the pharmacokinetics (PK) of galeterone novel oral formulations. Kramer, W, et al. 2013 American Society of Clinical Oncology (ASCO), Abstract #e16075 (publication-only).
February 15, 2013
Galeterone, Abiraterone, Orteronel and Ketoconazole Exhibit Differential Inhibitory Effects on CYP17 and Steroidogenesis. Jacoby, D. and Williams, M. 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Abstract #184.
June 3, 2012
Phase 1 clinical trial of galeterone (TOK-001) a multifunctional antiandrogen and CYP17 inhibitor in Castration Resistant Prostate Cancer (CRPC). Montgomery B, et al. 2012 Annual Meeting of the American Society of Clinical Oncology, Abstract 4665
April 3, 2012
ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naive patients with castration-resistant prostate cancer (CRPC). Taplin M, et al. American Association for Cancer Research Annual Meeting 2012, Abstract CT-07.
